Literature DB >> 35919531

ASK1 Inhibitor in Chronic Kidney Disease Therapy: From Bench to Bedside.

Lu Wen1,2, Qingqing Wei1.   

Abstract

Entities:  

Keywords:  ACEi; ASK1; CKD; chronic kidney disease; fibrosis; selonsertib

Mesh：

Substances：

Year:  2022        PMID： 35919531      PMCID： PMC9337900          DOI： 10.34067/KID.0002562022

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  14 in total

1.  Variants in ASK1 are associated with skeletal muscle ASK1 expression, in vivo insulin resistance, and type 2 diabetes in Pima Indians.

Authors:  Li Bian; Robert L Hanson; Victoria Ossowski; Kim Wiedrich; Clinton C Mason; Michael Traurig; Yunhua L Muller; Sayuko Kobes; William C Knowler; Leslie J Baier; Clifton Bogardus
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

2.  Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.

Authors:  Rohit Loomba; Mazen Noureddin; Kris V Kowdley; Anita Kohli; Aasim Sheikh; Guy Neff; Bal Raj Bhandari; Nadege Gunn; Stephen H Caldwell; Zachary Goodman; Ilan Wapinski; Murray Resnick; Andrew H Beck; Dora Ding; Catherine Jia; Jen-Chieh Chuang; Ryan S Huss; Chuhan Chung; G Mani Subramanian; Robert P Myers; Keyur Patel; Brian B Borg; Reem Ghalib; Heidi Kabler; John Poulos; Ziad Younes; Magdy Elkhashab; Tarek Hassanein; Rajalakshmi Iyer; Peter Ruane; Mitchell L Shiffman; Simone Strasser; Vincent Wai-Sun Wong; Naim Alkhouri
Journal:  Hepatology       Date:  2021-02       Impact factor: 17.425

3.  ASK1 contributes to fibrosis and dysfunction in models of kidney disease.

Authors:  John T Liles; Britton K Corkey; Gregory T Notte; Grant R Budas; Eric B Lansdon; Ford Hinojosa-Kirschenbaum; Shawn S Badal; Michael Lee; Brian E Schultz; Sarah Wise; Swetha Pendem; Michael Graupe; Laurie Castonguay; Keith A Koch; Melanie H Wong; Giuseppe A Papalia; Dorothy M French; Theodore Sullivan; Erik G Huntzicker; Frank Y Ma; David J Nikolic-Paterson; Tareq Altuhaifi; Haichun Yang; Agnes B Fogo; David G Breckenridge
Journal:  J Clin Invest       Date:  2018-07-19       Impact factor: 14.808

4.  ASK1-dependent endothelial cell activation is critical in ovarian cancer growth and metastasis.

Authors:  Mingzhu Yin; Huanjiao Jenny Zhou; Jiqin Zhang; Caixia Lin; Hongmei Li; Xia Li; Yonghao Li; Haifeng Zhang; David G Breckenridge; Weidong Ji; Wang Min
Journal:  JCI Insight       Date:  2017-09-21

5.  Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.

Authors:  Stephen A Harrison; Vincent Wai-Sun Wong; Takeshi Okanoue; Natalie Bzowej; Raj Vuppalanchi; Ziad Younes; Anita Kohli; Shiv Sarin; Stephen H Caldwell; Naim Alkhouri; Mitchell L Shiffman; Marianne Camargo; Georgia Li; Kathryn Kersey; Catherine Jia; Yanni Zhu; C Stephen Djedjos; G Mani Subramanian; Robert P Myers; Nadege Gunn; Aasim Sheikh; Quentin M Anstee; Manuel Romero-Gomez; Michael Trauner; Zachary Goodman; Eric J Lawitz; Zobair Younossi
Journal:  J Hepatol       Date:  2020-03-06       Impact factor: 25.083

Review 6.  ASK1: a new therapeutic target for kidney disease.

Authors:  Greg H Tesch; Frank Y Ma; David J Nikolic-Paterson
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-25

7.  Effects of Selonsertib in Patients with Diabetic Kidney Disease.

Authors:  Glenn M Chertow; Pablo E Pergola; Fang Chen; Brian J Kirby; John S Sundy; Uptal D Patel
Journal:  J Am Soc Nephrol       Date:  2019-09-10       Impact factor: 10.121

8.  Redundant role of ASK1-mediated p38MAPK activation in human platelet function.

Authors:  Kamila M Sledz; Samantha F Moore; Vijayasameerah Vijayaragavan; Shahida Mallah; Lucy J Goudswaard; Christopher M Williams; Roger W Hunter; Ingeborg Hers
Journal:  Cell Signal       Date:  2020-01-07       Impact factor: 4.315

9.  Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial.

Authors:  Stephan Rosenkranz; Jeremy Feldman; Vallerie V McLaughlin; Franz Rischard; Tobias J Lange; R James White; Andrew J Peacock; Felix Gerhardt; Ramin Ebrahimi; Gabriel Brooks; Carol Satler; Robert P Frantz
Journal:  Lancet Respir Med       Date:  2021-08-20       Impact factor: 30.700

10.  The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.

Authors:  Rohit Loomba; Eric Lawitz; Parvez S Mantry; Saumya Jayakumar; Stephen H Caldwell; Hays Arnold; Anna Mae Diehl; C Stephen Djedjos; Ling Han; Robert P Myers; G Mani Subramanian; John G McHutchison; Zachary D Goodman; Nezam H Afdhal; Michael R Charlton
Journal:  Hepatology       Date:  2017-12-26       Impact factor: 17.425
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.